ABLYNX ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BONDS
January 22 2018 - 1:02AM
REGULATED INFORMATION
GHENT, Belgium, 22 January 2018 - Ablynx
[Euronext Brussels and Nasdaq: ABLX] today announced, in
conformity with Title II of the Law of 2 May 2007 and the Royal
Decree of 14 February 2008, that an additional 218,998 new shares
have been issued by the Company in exchange for €1,689,981.62 as
the result of the exercise of warrants.
The Company also announced that in relation to
the €100,000,000, 3.25% Senior Unsecured Convertible Bonds due on
27 May 2020 (ISIN: BE6278650344) issued by the Company in the
denomination of €100,000 each (the "Bonds"), an additional 126,348
new shares were issued following the conversion of 16 Bonds.
As a result of these transactions, Ablynx now
has a share capital of €140,320,046.59 represented by a total
number of 75,065,990 shares, conferring a total number of
75,065,990 voting rights.
The current total number of outstanding rights
(warrants) to subscribe for not yet issued securities conferring
voting rights is 2,667,506, entitling their holders to subscribe
for a total number of 2,667,506 new shares, conferring a total
number of 2,667,506 voting rights.
The current total number of outstanding
convertible bonds is 984, which, on the basis of the current
conversion price of €12.6631, are convertible into 7,770,609 new
shares, conferring a total number of 7,770,609 voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in
the development of Nanobodies®, proprietary therapeutic proteins
based on single-domain antibody fragments, which combine the
advantages of conventional antibody drugs with some of the features
of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the
Company has more than 45 proprietary and partnered programmes in
development in various therapeutic areas including inflammation,
haematology, immuno-oncology, oncology and respiratory disease. The
Company has collaborations with multiple pharmaceutical companies
including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck &
Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo
Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please
contactAblynx:Dr Edwin MosesCEOt: +32 (0)9
262 00 07m: +32 (0)473 39 50 68e: edwin.moses@ablynx.com
Lies VannesteDirector Investor Relationst: +32 (0)9
262 01 37m: +32 (0)498 05 35 79 e:
lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations:Consilium Strategic
CommunicationsMary-Jane Elliott, Philippa Gardner, Sukaina
Virjit: +44 (0)20 3709 5700e:
ablynx@consilium-comms.com
Joele Frank, Wilkinson Brimmer KatcherDan
Katcher or Joseph Salat: +1 212-355-4449
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/f0ca429a-33b3-4fe8-90d7-d09b334987ac